Alectinib
Overview
Alectinib is an oral medication used for the treatment of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). It is a highly selective ALK inhibitor that improves progression-free survival in patients with advanced ALK-positive NSCLC.
Patent & exclusivity (US)
Per the FDA Orange Book (1 approved US product), the latest listed US patent on Alectinib expires 24 Apr 2035 and exclusivity 18 Apr 2031. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Alectinib? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.